Journal of Critical Care
Volume 24, Issue 4 , Pages 625.e9-625.e14 , December 2009

Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: Risk factors and mortality

References 

  1. Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin America medical centers: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother. 2003;52:140–141
  2. Goossens H. Susceptibility of multi-drug–resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect. 2003;9:980–983
  3. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med. 1999;20:303–316
  4. Deshpande LM, Fritsce TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: a global report of the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2004;49(4):231–236
  5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485
  6. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimiccrob Chemother. 2001;47:247–250
  7. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–48
  8. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa in hospitalized patients. Clin Infect Dis. 2002;34(3):340–345
  9. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997;25(5):1094–1098
  10. Cao B, Whang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112–118
  11. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect. 2005;59(2):96–101
  12. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. The imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns. 2005;31:870–873
  13. Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros EA. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil. A 7-year study. Infect Control Hosp Epidemiol. 2006;27(11):1270–1273
  14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control. 1988;16:128–140
  15. Kiska DL, Gilligan PH. Pseudomonas and Burkholderia. In:  Murray PR,  Baron EJ,  Pfaller MA, et al. editor. Manual of clinical microbiology. Washington, DC: American Society for Microbiology; 1995;p. 517–525
  16. National Committee for Clinical Laboratory Standards . Performance standards for antimicrobial disk susceptibility tests. Approved standard. NCCLS document M2-A5. 6th ed.. Wayne, PA: NCCCLS; 2000;
  17. Knaus WA, Draper EA, Wagner DP, Zimmermann JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–829
  18. Paterson DL. Looking for risk factors for acquisition of antibiotic resistance. A 21st century approach. Clin Infect Dis. 2002;34:1564–1567
  19. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001;32:1055–1061
  20. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis. 2002;34:1558–1563
  21. Fortaleza CM, Freire MP, Filho D de C, de Carvalho Ramos M. Risk factors for recovery of Imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol. 2006;27:901–906
  22. Schulgen G, Kropec A, Kappstein I, Daschner F, Schumacher M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol. 2000;53:409–417
  23. Falagas ME, Koletsi PK, Kopterides P, Michalopoulos A. Risk factors for isolation of strains susceptible only to polymyxins in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2006;50(7):2541–2543
  24. Lautenbach E, Weiner MG, Nachamkin I, Bilker W, Sheridan A, Fishman N. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006;27:893–900
  25. Paramythioutou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670–677
  26. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med. 2007;33(9):1524–1532
  27. Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother. 2007;51(6):1967–1971
  28. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect. 2004;57(3):209–216
  29. Gaynes RP, Culver DH. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect Control Hosp Epidemiol. 1992;13:10–14
  30. Gulay Z, Atay T, Amyes SG. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. J Chemother. 2001;13(5):546–554
  31. Bergmans D. Cross-colonization with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax. 1998;53:1053–1058
  32. Weist K, Pollege K, Schulz I, Ruden H, Gastmeier P. How many nosocomial infections are associated with cross-transmission? A prospective cohort study in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2002;23(3):127–132
  33. Grundmann H, Barwolff S, Tami A, et al. How many infections are caused by patient-to-patient transmission in intensive care unit?. Crit Care Med. 2005;33(5):946–951
  34. Halwani M, Solaymani-Dodaran M, Grundmann H, Coupland C, Slack R. Cross-transmission of nosocomial pathogens in an adult intensive care unit: incidence and risk factors. J Hosp Infect. 2006;63(1):39–46
  35. Carmeli Y, Trouillet N, Eliopoulos G, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382

PII: S0883-9441(09)00078-1

doi: 10.1016/j.jcrc.2009.03.006

Journal of Critical Care
Volume 24, Issue 4 , Pages 625.e9-625.e14 , December 2009

Article Tools